Mechanism of Action
- A humanised monoclonal antibody directed against the terminal complement protein C5 that inhibits its cleavage into C5a and C5b, thus preventing formation of the membrane attack complex.
- Paroxysmal nocturnal haemoglobinuria
- Atypical haemolytic uraemic syndrome (aHUS)
- Adverse Effects
- Nausea / vomiting
- Upper respiratory tract infection
- Meningococcal infection